Key Insights

Highlights

Success Rate

89% trial completion (above average)

Published Results

18 trials with published results (23%)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

7.7%

6 terminated out of 78 trials

Success Rate

88.9%

+2.4% vs benchmark

Late-Stage Pipeline

10%

8 trials in Phase 3/4

Results Transparency

38%

18 of 48 completed with results

Key Signals

18 with results89% success

Data Visualizations

Phase Distribution

63Total
Not Applicable (28)
P 1 (9)
P 2 (18)
P 3 (6)
P 4 (2)

Trial Status

Completed48
Unknown10
Recruiting9
Terminated6
Active Not Recruiting3
Not Yet Recruiting1

Trial Success Rate

88.9%

Benchmark: 86.5%

Based on 48 completed trials

Clinical Trials (78)

Showing 20 of 20 trials
NCT04804930RecruitingPrimary

Trichoscopy and Systemic Scleroderma

NCT02682511Phase 2Active Not Recruiting

Oral Ifetroban to Treat Diffuse Cutaneous Systemic Sclerosis (SSc) or SSc-associated Pulmonary Arterial Hypertension

NCT05171114Not ApplicableCompletedPrimary

Scleroderma: Functional Disability Between the Dominant and Contralateral Hand.

NCT07493395Phase 2Not Yet RecruitingPrimary

Phase IIa Trial of Anti-CD19 CAR T-Cells in Systemic Sclerosis Resistant to Immunosuppressive Therapy

NCT05559580Phase 2CompletedPrimary

A Study in People With Systemic Sclerosis to Test Whether Avenciguat (BI 685509) Has an Effect on Lung Function and Other Systemic Sclerosis Symptoms

NCT07472166Phase 4CompletedPrimary

Efficacy of Tofacitinib on Skin Thickening in Diffuse Cutaneous Systemic Sclerosis: A Comparative Study With Methotrexate

NCT04922736Not ApplicableActive Not RecruitingPrimary

Patient Reported Outcomes With UVA-1 Therapy for Treatment of Sclerosing Skin Diseases

NCT07345052RecruitingPrimary

Western Sweden Systemic Sclerosis Project

NCT05878717Phase 2Recruiting

A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease

NCT03559465Not ApplicableCompletedPrimary

Profibrosing Role of B Lymphocytes in Patients With Systemic Sclerosis.

NCT07292961Not ApplicableRecruiting

Investigating the Effectiveness of the Biopsychosocial Model-Based Exercise Approach in Children and Adults Diagnosed With Scleroderma

NCT06256575Not ApplicableRecruitingPrimary

Study of Diosmin for the Treatment of Digital Ulcers in Systemic Sclerosis

NCT06182293Not ApplicableRecruitingPrimary

Periodontal Microbiota in Systemic Sclerosis

NCT04683029Phase 2CompletedPrimary

A Study of Guselkumab in Participants With Systemic Sclerosis

NCT04837131Phase 2Terminated

A Study to Evaluate the Safety and Tolerability of Oral Ixazomib in Scleroderma-related Lung Disease Patients

NCT06338722Not ApplicableCompletedPrimary

Making it Work Program for Systemic Sclerosis

NCT00070590Phase 2Completed

Efficacy and Safety of Oral Bosentan in Pulmonary Fibrosis Associated With Scleroderma

NCT05622578Not ApplicableCompletedPrimary

Phenotyping of Chronic Pain in Diffused Systemic Scleroderma

NCT06697561Not ApplicableActive Not RecruitingPrimary

Development and Evaluation of an Evidence-based Education Program for People With Hand Dysfunction in Scleroderma

NCT05961267Completed

Study of Gynecological Follow-up of Patients With Autoimmune Disease or Inflammatory Rheumatism

Scroll to load more

Research Network

Activity Timeline